ヒドララジン-イソソルビド・ディニートレート (hydralazine-isosorbide dinitrate) の組み合わせが,左心室不全患者の運動能力と運動血動力学に及ぼす即効性
Circulation
|June 1, 1979
まとめ
ヒドララジンやイソソorbide dinitrateのような血管拡張剤は,急性閉塞性心不全 (CHF) 患者の最大運動能力を改善しません. しかし,低強度の運動で血液動力学を改善し,心臓発作患者の耐性を高める可能性があります.
科学分野:
- 心臓病学 心臓病学
- 運動生理学 運動生理学
- 薬理学 薬理学とは
背景:
- 閉塞性心不全 (CHF) 患者の血管拡張剤で休息時の血液動力学が改善されます.
- CHFにおける運動による血液動力学に対する血管拡張剤の影響は十分に理解されていません.
研究 の 目的:
- 口服用ヒドララジンとイソソorbide dinitrateが,心筋梗塞の患者における運動の血液動力学と運動能力に及ぼす急性効果を調査する.
主な方法:
- ランダム化,ダブルブラインド,プラセボ対照研究.
- クラスIIまたはIIIのCHFを患っている22人の患者は,自転車での運動を行った.
- ヒドララジン/イソソルビド・ディニートレートまたはプラセボの投与前後の測定値.
主要な成果:
- 最大運動期間と酸素消費量は,両群とも変わらなかった.
- サブマキシマル運動では,血管拡張剤群では心臓指数が増加し,全身血管抵抗が著しく低下した (p <0.05).
- どちらのグループでもピーク運動時に有意な血液動力学的変化は観察されなかった.
結論:
- ハイドララジンとイソソorbide dinitrateの急性投与は,CHF患者の最大運動能力を高めることはありません.
- 血管拡張剤は,サブマキシマル運動の血液動力学を改善し,潜在的に運動耐性を高め,CHFでより低い作業速度で運動耐性を高めることができます.
さらに関連する動画
関連する概念動画
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...